(19)
(11)EP 1 281 351 B8

(12)CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15)Correction information:
Corrected version no 1 (W1 B1)

(48)Corrigendum issued on:
04.03.2009 Bulletin 2009/10

(45)Mention of the grant of the patent:
05.11.2008 Bulletin 2008/45

(21)Application number: 02017012.2

(22)Date of filing:  27.07.2002
(51)International Patent Classification (IPC): 
G06F 19/00(2006.01)
A61M 5/00(2006.01)
A61B 5/00(2006.01)

(54)

Diabetes management system

Diabetisbehandlungssystem

Système de controle du diabète


(84)Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

(30)Priority: 31.07.2001 US 918623

(43)Date of publication of application:
05.02.2003 Bulletin 2003/06

(73)Proprietors:
  • Roche Diagnostics GmbH
    68305 Mannheim (DE)
    Designated Contracting States:
    DE 
  • F. Hoffmann-La Roche AG
    4070 Basel (CH)
    Designated Contracting States:
    AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR 

(72)Inventors:
  • Galley, Paul J.
    Indianapolis, IN 46229 (US)
  • Thukral, Ajay
    Indianapolis, IN 46256 (US)
  • Chittajallu, Siva K.
    Indianapolis, IN 46254 (US)
  • Weinert, Stefan
    Pendleton, IN 46064 (US)


(56)References cited: : 
EP-A- 1 102 194
WO-A-00/74753
US-A- 5 997 475
WO-A-00/18293
DE-A1- 19 814 219
US-A- 6 167 362
  
      
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).